{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:23:42Z","timestamp":1783002222861,"version":"3.54.5"},"reference-count":130,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.ctrv.2013.01.003","type":"journal-article","created":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T21:49:13Z","timestamp":1361310553000},"page":"664-672","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["Effect of inhibition of the FGFR\u2013MAPK signaling pathway on the development of ocular toxicities"],"prefix":"10.1016","volume":"39","author":[{"given":"Ruud","family":"van der Noll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Leijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido H.G.","family":"Neuteboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2013.01.003_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7243\/2049-7962-1-5","article-title":"Ocular adverse effects of anti-cancer chemotherapy and targeted therapy","volume":"1","author":"Singh","year":"2012","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.ctrv.2013.01.003_b0010","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1200\/JCO.2011.41.5851","article-title":"Ocular toxicity of targeted therapies","volume":"30","author":"Renouf","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0015","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1158\/1078-0432.CCR-12-0868","article-title":"Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors","volume":"18","author":"Leijen","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0020","series-title":"Webvision: the organization of the retina and visual system [Internet] PubMed Bookshelf ID: NBK11530","article-title":"The retinal pigment epithelium","author":"Strauss","year":"1995"},{"key":"10.1016\/j.ctrv.2013.01.003_b0025","series-title":"Ocular disease: mechanisms and management","first-page":"554","article-title":"Retinal detachment","author":"Fisher","year":"2010"},{"key":"10.1016\/j.ctrv.2013.01.003_b0030","first-page":"10","article-title":"The onset of pigment epithelial proliferation after retinal detachment","volume":"21","author":"Anderson","year":"1981","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ctrv.2013.01.003_b0035","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.media.2011.06.005","article-title":"Automated macular pathology diagnosis in retinal OCT images using multi-scale spatial pyramid and local binary patterns in texture and shape encoding","volume":"15","author":"Liu","year":"2011","journal-title":"Med Image Anal"},{"key":"10.1016\/j.ctrv.2013.01.003_b0040","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0002-9394(03)00792-X","article-title":"Optical coherence tomography to detect and manage retinal disease and glaucoma","volume":"137","author":"Jaffe","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0045","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00006982-200306000-00009","article-title":"Optical coherence tomography of branch retinal vein occlusion","volume":"23","author":"Spaide","year":"2003","journal-title":"Retina"},{"key":"10.1016\/j.ctrv.2013.01.003_b0050","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.survophthal.2007.02.008","article-title":"Retinal pigment epithelial detachment","volume":"52","author":"Zayit-Soudry","year":"2007","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0055","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/mt.2008.10","article-title":"Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator","volume":"16","author":"Campochiaro","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.ctrv.2013.01.003_b0060","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s10384-011-0016-4","article-title":"Vitreous inflammatory factors in macular edema with central retinal vein occlusion","volume":"55","author":"Noma","year":"2011","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0065","doi-asserted-by":"crossref","first-page":"e8158","DOI":"10.1371\/journal.pone.0008158","article-title":"Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases","volume":"4","author":"Yoshimura","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2013.01.003_b0070","first-page":"755","article-title":"Fluorescein fundus photography: an aid in the differential diagnosis of posterior ocular lesions","volume":"68","author":"Norton","year":"1964","journal-title":"Trans Am Acad Ophthalmol Otolaryngol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0075","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s12325-010-0089-3","article-title":"Management of macular edema secondary to branch retinal vein occlusion: an evidence-based update","volume":"28","author":"Aref","year":"2011","journal-title":"Adv Ther"},{"key":"10.1016\/j.ctrv.2013.01.003_b0080","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1111\/j.1538-7836.2010.03909.x","article-title":"Retinal vein thrombosis: pathogenesis and management","volume":"8","author":"Rehak","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ctrv.2013.01.003_b0085","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","article-title":"Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ctrv.2013.01.003_b0090","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1002\/j.1460-2075.1990.tb07454.x","article-title":"Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors","volume":"9","author":"Dionne","year":"1990","journal-title":"EMBO J"},{"key":"10.1016\/j.ctrv.2013.01.003_b0095","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1006\/exer.2000.0984","article-title":"Cellular and subcellular patterns of expression of bFGF and CNTF in the normal and light stressed adult rat retina","volume":"72","author":"Walsh","year":"2001","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0100","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1006\/exer.2001.1078","article-title":"Neurotrophic signaling in normal and degenerating rodent retinas","volume":"73","author":"Wahlin","year":"2001","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0105","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1046\/j.1471-4159.2000.0751520.x","article-title":"The FGFR1 inhibitor PD 173074 selectively and potently antagonizes FGF-2 neurotrophic and neurotropic effects","volume":"75","author":"Skaper","year":"2000","journal-title":"J Neurochem"},{"key":"10.1016\/j.ctrv.2013.01.003_b0110","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1038\/sj.onc.1205765","article-title":"CAMP inhibits the proliferation of retinal pigmented epithelial cells through the inhibition of ERK1\/2 in a PKA-independent manner","volume":"21","author":"Hecquet","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2013.01.003_b0115","first-page":"3091","article-title":"Activation and role of MAP kinase-dependent pathways in retinal pigment epithelial cells: ERK and RPE cell proliferation","volume":"43","author":"Hecquet","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Pt 2","key":"10.1016\/j.ctrv.2013.01.003_b0120","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/eye.1994.54","article-title":"Development, repair and regeneration of the retinal pigment epithelium","volume":"8","author":"Grierson","year":"1994","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ctrv.2013.01.003_b0125","doi-asserted-by":"crossref","first-page":"22367","DOI":"10.1074\/jbc.273.35.22367","article-title":"Endogenous FGF1-induced activation and synthesis of extracellular signal-regulated kinase 2 reduce cell apoptosis in retinal-pigmented epithelial cells","volume":"273","author":"Guillonneau","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2013.01.003_b0130","first-page":"839","article-title":"Growth factor responsiveness of human retinal pigment epithelial cells","volume":"31","author":"Leschey","year":"1990","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ctrv.2013.01.003_b0135","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.1038\/sj.onc.1203200","article-title":"Both FGF1 and bcl-x synthesis are necessary for the reduction of apoptosis in retinal pigmented epithelial cells by FGF2: role of the extracellular signal-regulated kinase 2","volume":"18","author":"Bryckaert","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2013.01.003_b0140","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1038\/sj.onc.1203872","article-title":"Regulation of proliferation-survival decisions is controlled by FGF1 secretion in retinal pigmented epithelial cells","volume":"19","author":"Bryckaert","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2013.01.003_b0145","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1471-4159.2000.0750151.x","article-title":"Endogenous and exogenous fibroblast growth factor 2 support survival of chick retinal neurons by control of neuronal neuronal bcl-x(L) and bcl-2 expression through a fibroblast berowth factor receptor 1- and ERK-dependent pathway","volume":"75","author":"Desire","year":"2000","journal-title":"J Neurochem"},{"key":"10.1016\/j.ctrv.2013.01.003_b0150","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1471-4159.2005.03510.x","article-title":"Fibroblast growth factor 2 applied to the optic nerve after axotomy up-regulates BDNF and TrkB in ganglion cells by activating the ERK and PKA signaling pathways","volume":"96","author":"Soto","year":"2006","journal-title":"J Neurochem"},{"key":"10.1016\/j.ctrv.2013.01.003_b0155","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/j.1471-4159.2005.03129.x","article-title":"Fibroblast growth factor 2 applied to the optic nerve after axotomy increases Bcl-2 and decreases Bax in ganglion cells by activating the extracellular signal-regulated kinase signaling pathway","volume":"93","author":"Rios-Munoz","year":"2005","journal-title":"J Neurochem"},{"key":"10.1016\/j.ctrv.2013.01.003_b0160","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/347083a0","article-title":"Photoreceptor degeneration in inherited retinal dystrophy delayed by basic fibroblast growth factor","volume":"347","author":"Faktorovich","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2013.01.003_b0165","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1523\/JNEUROSCI.12-09-03554.1992","article-title":"Basic fibroblast growth factor and local injury protect photoreceptors from light damage in the rat","volume":"12","author":"Faktorovich","year":"1992","journal-title":"J Neurosci"},{"key":"10.1016\/j.ctrv.2013.01.003_b0170","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/glia.20868","article-title":"Mitogen-activated protein kinase-signaling regulates the ability of Muller glia to proliferate and protect retinal neurons against excitotoxicity","volume":"57","author":"Fischer","year":"2009","journal-title":"Glia"},{"key":"10.1016\/j.ctrv.2013.01.003_b0175","doi-asserted-by":"crossref","first-page":"5098","DOI":"10.1167\/iovs.06-0318","article-title":"Protection of RPE cells from oxidative injury by 15-deoxy-delta12,14-prostaglandin J2 by augmenting GSH and activating MAPK","volume":"47","author":"Qin","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ctrv.2013.01.003_b0180","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/jcp.1041540323","article-title":"Fibroblast growth factor receptor deficiency in dystrophic retinal pigmented epithelium","volume":"154","author":"Malecaze","year":"1993","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0185","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1076\/ceyr.17.5.494.5186","article-title":"Continuous exposure to bright light upregulates bFGF and CNTF expression in the rat retina","volume":"17","author":"Wen","year":"1998","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0190","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1755-148X.2011.00935.x","article-title":"MEK-ERK and heparin-susceptible signaling pathways are involved in cell-cycle entry of the wound edge retinal pigment epithelium cells in the adult newt","volume":"25","author":"Yoshikawa","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0195","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1242\/dev.113.2.577","article-title":"Basic fibroblast growth factor induces retinal pigment epithelium to generate neural retina in vitro","volume":"113","author":"Pittack","year":"1991","journal-title":"Development"},{"key":"10.1016\/j.ctrv.2013.01.003_b0200","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1242\/dev.124.4.805","article-title":"Fibroblast growth factors are necessary for neural retina but not pigmented epithelium differentiation in chick embryos","volume":"124","author":"Pittack","year":"1997","journal-title":"Development"},{"key":"10.1016\/j.ctrv.2013.01.003_b0205","first-page":"57","article-title":"Retina regeneration in the chick embryo is not induced by spontaneous Mitf downregulation but requires FGF\/FGFR\/MEK\/Erk dependent upregulation of Pax6","volume":"13","author":"Spence","year":"2007","journal-title":"Mol Vis"},{"key":"10.1016\/j.ctrv.2013.01.003_b0210","first-page":"1000","article-title":"Retinal regeneration in the Xenopus laevis tadpole: a new model system","volume":"15","author":"Vergara","year":"2009","journal-title":"Mol Vis"},{"key":"10.1016\/j.ctrv.2013.01.003_b0215","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3109\/02713689508998406","article-title":"The effects of bFGF on RCS rat eyes","volume":"14","author":"Perry","year":"1995","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0220","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0014-5793(96)00461-9","article-title":"Analysis of basic fibroblast growth factor in rats with inherited retinal degeneration","volume":"387","author":"McLaren","year":"1996","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ctrv.2013.01.003_b0225","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1523\/JNEUROSCI.16-05-01679.1996","article-title":"Retinal degeneration in transgenic mice with photoreceptor-specific expression of a dominant-negative fibroblast growth factor receptor","volume":"16","author":"Campochiaro","year":"1996","journal-title":"J Neurosci"},{"key":"10.1016\/j.ctrv.2013.01.003_b0230","first-page":"1363","article-title":"FGFR1, signaling, and AP-1 expression after retinal detachment: reactive Muller and RPE cells","volume":"42","author":"Geller","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ctrv.2013.01.003_b0235","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1089\/jop.2009.0060","article-title":"PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion","volume":"25","author":"Huang","year":"2009","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.ctrv.2013.01.003_b0240","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/bjo.82.2.181","article-title":"Platelet derived growth factor and fibroblast growth factor basic levels in the vitreous of patients with vitreoretinal disorders","volume":"82","author":"Cassidy","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0245","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0002-9394(01)01125-4","article-title":"Levels of basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in subretinal fluid from patients with retinal detachment","volume":"132","author":"La Heij","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0250","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1471-4159.2007.05189.x","article-title":"Basic fibroblast growth factor-induced protection from light damage in the mouse retina in vivo","volume":"105","author":"O\u2019Driscoll","year":"2008","journal-title":"J Neurochem"},{"key":"10.1016\/j.ctrv.2013.01.003_b0255","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1167\/iovs.08-2439","article-title":"Phosphatidylinositol 3 kinase pathway and 4-hydroxy-2-nonenal-induced oxidative injury in the RPE","volume":"50","author":"Chen","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ctrv.2013.01.003_b0260","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.exer.2010.03.002","article-title":"PI3K\/Akt and mTOR\/p70S6K pathways mediate neuroprotectin D1-induced retinal pigment epithelial cell survival during oxidative stress-induced apoptosis","volume":"90","author":"Faghiri","year":"2010","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0265","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2013.01.003_b0270","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2013.01.003_b0275","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0898-6568(01)00192-9","article-title":"Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity","volume":"13","author":"Liebmann","year":"2001","journal-title":"Cell Signal"},{"key":"10.1016\/j.ctrv.2013.01.003_b0280","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3322\/canjclin.44.3.160","article-title":"Oncogenes and tumor suppressor genes","volume":"44","author":"Weinberg","year":"1994","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2013.01.003_b0285","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1517\/13543784.2011.548803","article-title":"Novel mitogen-activated protein kinase kinase inhibitors","volume":"20","author":"Chapman","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ctrv.2013.01.003_b0290","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.canlet.2009.01.022","article-title":"Targeting the RAF-MEK-ERK pathway in cancer therapy","volume":"283","author":"Montagut","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2013.01.003_b0295","first-page":"4682","article-title":"Ras oncogenes in human cancer: a review","volume":"49","author":"Bos","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0300","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2013.01.003_b0305","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1158\/1078-0432.CCR-10-2727","article-title":"FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo","volume":"17","author":"Sharpe","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0310","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/0008-5472.CAN-07-5229","article-title":"FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival","volume":"68","author":"Kunii","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0315","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.bjc.6606016","article-title":"Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo","volume":"104","author":"Lamont","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2013.01.003_b0320","doi-asserted-by":"crossref","first-page":"62ra93","DOI":"10.1126\/scitranslmed.3001451","article-title":"Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer","volume":"2","author":"Weiss","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2013.01.003_b0325","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nm0897-887","article-title":"Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth","volume":"3","author":"Wang","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2013.01.003_b0330","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/1078-0432.CCR-07-4790","article-title":"Advances in targeting the Ras\/Raf\/MEK\/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy","volume":"14","author":"Friday","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0335","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/PAP.0b013e3181c6962f","article-title":"KRAS mutation testing in human cancers: the pathologist\u2019s role in the era of personalized medicine","volume":"17","author":"Wang","year":"2010","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0340","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1158\/1078-0432.CCR-08-0333","article-title":"Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway","volume":"14","author":"Sebolt-Leopold","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0345","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nrm1498","article-title":"The RAF proteins take centre stage","volume":"5","author":"Wellbrock","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0350","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1158\/1078-0432.CCR-11-1491","article-title":"Phase II, open-label, randomized trial of the MEK1\/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma","volume":"18","author":"Kirkwood","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0355","article-title":"A phase II study of the MEK1\/MEK2 inhibitor GSK1120212 in metastatic BRAF-V600E or K mutant cutaneous melanoma patients previously treated with or without a BRAF inhibitor","volume":"24","author":"Kim","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0360","doi-asserted-by":"crossref","unstructured":"Weekes CD, Von Hoff DD, Adjei AA et al. A multi-center phase i, dose-escalation trial to the safety and pharmacokinetics\/pharmacodynamics of BAY 86\u20139766 (RDEA119), a MEK inhibitor, in advanced cancer patients. In: Presented at the 22nd EORTC-NCI-AACR Symposium on \u201cMolecular targets and cancer therapeutics\u201d, Berlin, November 16\u201319 2010.","DOI":"10.1016\/S1359-6349(10)72075-9"},{"issue":"7","key":"10.1016\/j.ctrv.2013.01.003_b0365","article-title":"Clinical pharmacokinetic (PK) and pharmacodynamic (PD) results of first-in-man phase I trial of the orally available MEK-inhibitor MSC1936369 (AS703026) in patients (pts) with advanced solid tumors","volume":"8","author":"Awada","year":"2010","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.ctrv.2013.01.003_b0370","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.14585","article-title":"A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors","volume":"26","author":"Rosen","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0375","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(12)70270-X","article-title":"Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial","volume":"13","author":"Infante","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0380","unstructured":"Zelboraf FDA approval; Highlights of prescribing information. 2011."},{"key":"10.1016\/j.ctrv.2013.01.003_b0385","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2013.01.003_b0390","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"issue":"15s","key":"10.1016\/j.ctrv.2013.01.003_b0395","article-title":"Phase I\/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors","volume":"28","author":"Kefford","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0400","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2013.01.003_b0405","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2013.01.003_b0410","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/annonc\/mdq599","article-title":"A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors","volume":"22","author":"Jonker","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0415","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1158\/1078-0432.CCR-11-1991","article-title":"Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma","volume":"18","author":"Finn","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0420","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1158\/1078-0432.CCR-07-1466","article-title":"A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors","volume":"14","author":"Sarker","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0425","doi-asserted-by":"crossref","first-page":"7451","DOI":"10.1158\/1078-0432.CCR-11-1747","article-title":"Phase I\/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma","volume":"17","author":"Kim","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0430","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-10-0379","article-title":"Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors","volume":"9","author":"Okamoto","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2013.01.003_b0435","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2010.33.5208","article-title":"Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer","volume":"29","author":"Ledermann","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0440","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1158\/1078-0432.CCR-10-2638","article-title":"Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors","volume":"17","author":"Yamada","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0445","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/bjc.2012.154","article-title":"A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours","volume":"106","author":"Boss","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2013.01.003_b0450","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1021\/jm051106d","article-title":"Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor","volume":"49","author":"Bhide","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2013.01.003_b0455","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1182\/blood-2004-10-3913","article-title":"CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma","volume":"105","author":"Trudel","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2013.01.003_b0460","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1021\/jm900431g","article-title":"Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)","volume":"52","author":"Roth","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2013.01.003_b0465","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.23131","article-title":"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition","volume":"122","author":"Matsui","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2013.01.003_b0470","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ajo.2006.10.004","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study","volume":"143","author":"Chen","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0475","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1158\/0008-5472.CAN-11-3034","article-title":"AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family","volume":"72","author":"Gavine","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0480","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1021\/jm2006222","article-title":"Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase","volume":"54","author":"Guagnano","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2013.01.003_b0485","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0042-6989(01)00212-7","article-title":"Animal models in research on retinal degenerations: past progress and future hope","volume":"42","author":"Chader","year":"2002","journal-title":"Vision Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0490","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/01.NCC.0000281759.23823.82","article-title":"Ocular toxicities of epidermal growth factor receptor inhibitors and their management","volume":"30","author":"Basti","year":"2007","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.ctrv.2013.01.003_b0495","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","article-title":"Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors","volume":"30","author":"Bendell","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0500","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.3005","article-title":"First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advance solid tumors","volume":"28","author":"Burris","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0505","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.3018","article-title":"Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumos (study P3K112826)","volume":"29","author":"Munster","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0510","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/08820530490520040","article-title":"Medical treatment of retinal vein occlusions","volume":"19","author":"Parodi","year":"2004","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0515","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11739-010-0478-2","article-title":"Retinal vein occlusions: a review for the internist","volume":"6","author":"Marcucci","year":"2011","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.ctrv.2013.01.003_b0520","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1158\/1078-0432.CCR-09-1920","article-title":"A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer","volume":"16","author":"Haura","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0525","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1600-0420.2006.00676.x","article-title":"Macular recovery after retinal detachment","volume":"84","author":"Abouzeid","year":"2006","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.ctrv.2013.01.003_b0530","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1200\/JCO.2004.01.185","article-title":"Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer","volume":"22","author":"Rinehart","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0535","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/10533","article-title":"Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo","volume":"5","author":"Sebolt-Leopold","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2013.01.003_b0540","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00280-011-1620-1","article-title":"Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer","volume":"68","author":"Boasberg","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0545","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nrc1503","article-title":"Targeting the mitogen-activated protein kinase cascade to treat cancer","volume":"4","author":"Sebolt-Leopold","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2013.01.003_b0550","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.2007.14.4956","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers","volume":"26","author":"Adjei","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0555","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-06-1150","article-title":"Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1\/2 inhibitor","volume":"13","author":"Yeh","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0560","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1158\/1078-0432.CCR-09-2483","article-title":"The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1\/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer","volume":"16","author":"Banerji","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0565","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.9033","article-title":"AZD6244 (ARRY-142886) vs temozolomide in patients with advanced melanoma: an open-label, randomized, multicenter, phase II study","volume":"26","author":"Dummer","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.ctrv.2013.01.003_b0570","article-title":"Safety and efficacy results from the first-in-human study of the oral MEK 1\/2 inhibitor GSK1120212","volume":"28","author":"Infante","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0575","first-page":"23","article-title":"Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1\/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo","volume":"39","author":"Yamaguchi","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0580","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1470-2045(12)70269-3","article-title":"Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial","volume":"13","author":"Falchook","year":"2012","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2013.01.003_b0585","article-title":"A phase Ib study of the MEK inhibitor GSK1120212 combined with gemcitabine i patients with solid tumors: Interim results","volume":"29","author":"Tolcher","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0590","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/JCO.2012.43.5966","article-title":"Phase II study of the MEK1\/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor","volume":"31","author":"Kim","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0595","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bmcl.2011.01.062","article-title":"Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent","volume":"21","author":"Isshiki","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ctrv.2013.01.003_b0600","article-title":"XL518, a potent selevtive orally bioavailable MEK1 inhibitor, downregulates the RAS\/RAF\/MEK\/ERK pathway in vivo, resulting in tumor growth inhibition and regression in pre-clinical models","volume":"6","author":"Johnston","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2013.01.003_b0605","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1158\/0008-5472.CAN-09-0679","article-title":"RDEA119\/BAY 869766: a potent, selective, allosteric inhibitor of MEK1\/2 for the treatment of cancer","volume":"69","author":"Iverson","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0610","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.bmcl.2011.01.071","article-title":"Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer","volume":"21","author":"Dong","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ctrv.2013.01.003_b0615","unstructured":"Hoffman-La Roche Limited. Zelboraf Product Monograph. 2012 Feb 2012."},{"key":"10.1016\/j.ctrv.2013.01.003_b0620","article-title":"BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E muttion-positive metastatic melanoma","volume":"29","author":"Ribas","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0625","doi-asserted-by":"crossref","first-page":"11100","DOI":"10.1158\/0008-5472.CAN-06-2554","article-title":"Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885","volume":"66","author":"King","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0630","article-title":"BREAK-2: a phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF mutation-positive (V600E\/K) metastatic melanoma","volume":"24","author":"Trefzer","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ctrv.2013.01.003_b0635","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.3513","article-title":"A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors","volume":"27","author":"Schwartz","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0640","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.bmcl.2011.11.060","article-title":"Small molecule inhibitors of BRAF in clinical trials","volume":"22","author":"Zambon","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"issue":"15","key":"10.1016\/j.ctrv.2013.01.003_b0645","article-title":"Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma","volume":"29","author":"Sharfman","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2013.01.003_b0650","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ajo.2007.04.007","article-title":"Tomographic features of serous retinal detachment with multilobular dye pooling in acute Vogt-Koyanagi-Harada disease","volume":"144","author":"Yamaguchi","year":"2007","journal-title":"Am J Ophthalmol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737213000133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737213000133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:56:04Z","timestamp":1644368164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737213000133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":130,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0305737213000133"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2013.01.003","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of inhibition of the FGFR\u2013MAPK signaling pathway on the development of ocular toxicities","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2013.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}